Clinical data
Pronunciation al-FYOO-zoe-sin
Trade names Uroxatral, others
AHFS/ Monograph
MedlinePlus a64002
  • AU: B2
  • US: B (No risk in non-human studies)
Routes of
By mouth (tablets)
ATC code G04CA01 (WHO)
Legal status
Legal status
Pharmacokinetic data
Bioavailability 49%
Protein binding 82–90%
Metabolism Liver (CYP3A4-mediated)
Biological half-life 10 hours
Excretion Feces (69%) and Urine (24%)
CAS Number 81403-80-7 YesY
PubChem (CID) 2092
DrugBank DB00346 YesY
ChemSpider 2008 YesY
UNII 90347YTW5F YesY
KEGG D07124 YesY
ChEBI CHEBI:51141 YesY
Chemical and physical data
Formula C19H27N5O4
Molar mass 389.449 g/mol
3D model (Jmol) Interactive image

Alfuzosin (INN, provided as the hydrochloride salt) is a pharmaceutical drug of the α1 blocker class. As an antagonist of the α1 adrenergic receptor, it works by relaxing the muscles in the prostate and bladder neck, making it easier to urinate. It is thus used to treat benign prostatic hyperplasia (BPH).

Alfuzosin is marketed in the United States by Sanofi Aventis under the brand name Uroxatral and elsewhere under the tradenames Xat, Xatral, Prostetrol and Alfural. Alfuzosin was approved by the U.S. FDA for treatment of BPH in June 2003.

Side effects

The most common side effects are dizziness (due to postural hypotension), upper respiratory tract infection, headache, fatigue, and abdominal disturbances.


Alfuzosin should be used with caution in patients with severe renal insufficiency, and should not be prescribed to patients with a known history of QT prolongation who are taking medications known to prolong the QT interval.

External links

This article is issued from Wikipedia - version of the 12/2/2016. The text is available under the Creative Commons Attribution/Share Alike but additional terms may apply for the media files.